Literature DB >> 3882246

Macrophage-mediated mitogenic suppression induced in mice of the C3H lineage by a vaccine strain of Salmonella typhimurium.

J C Lee, C W Gibson, T K Eisenstein.   

Abstract

Salmonella typhimurium, strain SL3235, an avirulent organism, has been used as a live vaccine in mice of the C3H lineage and has been found to confer high levels of protection. In the present study, it was found that intraperitoneal injection of approximately 5 X 10(5) live SL3235 induced potent suppression of spleen cell mitogenic responses to a panel of B- and T-cell mitogens in the Salmonella-hypersusceptible C3H/HeJ and C3HeB/FeJ, and the inherently resistant C3H/HeNCrlBR mice. Maximal suppression (greater than 99%) was seen at 1 week, and was still significant but waning (50%) at 3 weeks postimmunization. In contrast, cells of mice receiving acetone-killed cells were not suppressed. Removal of macrophages, but not T or B cells, restored responsiveness, indicating that suppression was macrophage mediated. Prostaglandins were not the major mediator of suppression, as in vitro administration of indomethacin failed to abrogate suppression. As mitogenic suppression occurred in mice with high levels of Salmonella immunity, the suppression is interpreted as a marker of a powerful immunomodulatory process induced by live cells, rather than as an indication of poor immune status of the host.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882246     DOI: 10.1016/0008-8749(85)90033-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  20 in total

Review 1.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

2.  Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909.

Authors:  Rezwanul Wahid; Rosangela Salerno-Gonçalves; Carol O Tacket; Myron M Levine; Marcelo B Sztein
Journal:  Vaccine       Date:  2006-11-03       Impact factor: 3.641

3.  Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.

Authors:  J X Bao; J D Clements
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  Outsmarting the host: bacteria modulating the immune response.

Authors:  Matthew D Woolard; Jeffrey A Frelinger
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

6.  Salmonella typhimurium infection in mice induces nitric oxide-mediated immunosuppression through a natural killer cell-dependent pathway.

Authors:  M G Schwacha; J J Meissler; T K Eisenstein
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing.

Authors:  K Denich; P Börlin; P D O'Hanley; M Howard; A W Heath
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Role of gamma interferon in late stages of murine salmonellosis.

Authors:  A Muotiala; P H Mäkelä
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Virulent Salmonella typhimurium-induced lymphocyte depletion and immunosuppression in chickens.

Authors:  J O Hassan; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.